Stock 6564 ENIMMUNE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Enimmune corporation

Equities

6564

TW0006564008

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 03:30:00 28/06/2024 am IST 		5-day change 1st Jan Change
35 TWD -0.85% Intraday chart for Enimmune corporation +1.01% -6.67%
13/03 Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,020 1,050 2,682 2,367 4,020 2,468
Enterprise Value (EV) 1 793.6 884 2,268 2,025 3,563 2,148
P/E ratio -10.5 x -18.5 x -31.9 x -49.9 x -15.7 x -11 x
Yield - - - - - -
Capitalization / Revenue 880 x 540 x 117 x 21.6 x 21.3 x 56.7 x
EV / Revenue 685 x 455 x 99.2 x 18.4 x 18.9 x 49.4 x
EV / EBITDA -7.99 x -13.4 x -29.9 x -40.4 x -12.8 x -9.11 x
EV / FCF -15.8 x -18.3 x -25.2 x -32.7 x -27.9 x -40.3 x
FCF Yield -6.33% -5.45% -3.96% -3.06% -3.59% -2.48%
Price to Book 2.87 x 3.24 x 4.34 x 4.15 x 7.38 x 7.66 x
Nbr of stocks (in thousands) 40,000 44,000 60,000 60,000 65,800 65,800
Reference price 2 25.51 23.86 44.70 39.45 61.10 37.50
Announcement Date 17/04/19 22/04/20 20/04/21 26/04/22 21/04/23 25/04/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1.159 1.944 22.88 109.8 188.4 43.49
EBITDA 1 -99.35 -65.98 -75.77 -50.18 -278.2 -235.9
EBIT 1 -104.3 -71.87 -82.72 -58.67 -286.4 -243.5
Operating Margin -8,999.31% -3,696.81% -361.61% -53.42% -152.01% -559.79%
Earnings before Tax (EBT) 1 -100.8 -56.64 -74.45 -47.25 -267.1 -237.7
Net income 1 -100.8 -56.64 -74.45 -47.25 -248 -223.7
Net margin -8,696.03% -2,913.84% -325.46% -43.02% -131.6% -514.42%
EPS 2 -2.438 -1.287 -1.400 -0.7900 -3.882 -3.400
Free Cash Flow 1 -50.25 -48.2 -89.84 -61.94 -127.9 -53.27
FCF margin -4,336.04% -2,479.51% -392.71% -56.4% -67.88% -122.47%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 17/04/19 22/04/20 20/04/21 26/04/22 21/04/23 25/04/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 227 166 414 342 457 319
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -50.3 -48.2 -89.8 -61.9 -128 -53.3
ROE (net income / shareholders' equity) -25.6% -16.1% -15.8% -7.96% -43.2% -43.3%
ROA (Net income/ Total Assets) -16.2% -12.6% -10.5% -5.79% -25.8% -22.1%
Assets 1 622.8 451.2 710.7 816.7 959.4 1,014
Book Value Per Share 2 8.880 7.360 10.30 9.500 8.280 4.890
Cash Flow per Share 2 5.230 2.780 1.730 1.970 5.990 5.470
Capex - - 4.19 2.98 0.35 -
Capex / Sales - - 18.32% 2.71% 0.18% -
Announcement Date 17/04/19 22/04/20 20/04/21 26/04/22 21/04/23 25/04/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ENIMMUNE CORPORATION Stock Enimmune corporation
-6.67% 70.89M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
ARGENX SE Stock argenx SE
+18.95% 26.02B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
GENMAB A/S Stock Genmab A/S
-19.03% 15.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6564 Stock
  4. Financials Enimmune corporation